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t(3;17)(q26;q22) G-banding – Coutesy Melanie Zenger and Claudia Haferlach. 
Clinics and pathology 
Disease 
Chronic myelogenous leukaemia with t(9;22)(q34;q11) 
and blast crisis of CML (BC-CML) (4 cases 
altogether), other myeloproliferative syndromes, Acute 
myeloid leukaemia (AML) in 4 cases (one M1, 2 
therapy related AML,one of which after breast cancer). 
Epidemiology 
At least 9 cases to date, aged 62 years (median, range: 





Sole anomaly in 3 cases, with t(9;22)(q34;q11) in 4 
cases (one of which was a complex translocation), with 




Genes involved and Proteins 




Transcrition factor; EVI1 targets include: GATA2, 
ZBTB16/PLZF, ZFPM2/FOG2, JNK and the 
PI3K/AKT pathway. Role in cell cycle progression, 
likely to be cell-type dependant; antiapoptotic factor; 
involved in neuronal development organogenesis; role 
in hematopoietic differentiation. 
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